UPDATE: Corrected to reflect that HeartFlow won a positive review, not reimbursement, and the source was a press release, not an SEC filing.
HeartFlow said today it won a positive healthcare evidence review from Blue Cross Blue Shield’s Evidence Street for its HeartFlow FFRct technology.
In the review, BCBS’s Evidence Street determined that the FFRct technology “provides a meaningful improvement in net health outcome when used to guide the care of patients with stable chest pain who are at immediate risk of CAD and are being considered for invasive coronary angiography,” according to a press release.
“This marks a major milestone achievement for HeartFlow and our FFRct technology because BCBS’s Evidence Street is among the world’s most rigorous health technology assessments and has significant global reach and influence. With BCBS insuring one in three Americans, substantially more patients with suspected CAD in the United States who are part of BCBS plans will be able to access this innovative non-invasive technology. HeartFlow FFRct also could now more rapidly become the standard of care, potentially improving clinical outcomes and saving global healthcare systems billions of dollars annually,” CEO Dr. John Stevens said in a press release.
In March, Siemens (NYSE:SI) Healthineers and Heartflow said yesterday they inked a global collaborative deal to develop a solution for diagnosing and managing patients with suspected coronary artery disease.
The collaborative deal will join CT Scanners from Siemens Healthineers with HeartFlow’s FFRct Analysis fractional flow reserve software to create personalized 3D models of each patients’ arteries while computer algorithms simulate blood flow and look for arterial blockages.